At the forefront of leukemia research, City of Hope will present pivotal results from the Paradigm trial—a phase 2, randomized, multi-center study comparing the efficacy of azacitidine combined with venetoclax against conventional induction chemotherapy in newly diagnosed, fit adults suffering from acute myeloid leukemia (AML). This investigation delves into novel therapeutic regimens aiming to enhance treatment responses while minimizing toxicity profiles. Dr. Ibrahim Aldoss, a distinguished hematologist, leads these efforts to redefine AML management based on molecular and functional disease characteristics.

Another critical leukemia-related highlight involves CD19-directed chimeric antigen receptor (CAR) T cell therapy deployed as a definitive consolidation strategy in older adults diagnosed with B-cell acute lymphoblastic leukemia (b-ALL) in their first complete remission. This advanced immunotherapy modality has demonstrated safety and therapeutic durability in maintaining minimal residual disease (MRD) negativity, a key prognostic marker that correlates with long-term survival. The application of CAR T cells in this demographic represents a transformative approach overcoming limitations traditionally faced by the elderly in tolerating intensive chemotherapy.

In the realm of lymphoma, City of Hope researchers will share a significant three-year follow-up analysis from the S1826 study. This data corroborates the superior progression-free survival observed with the immune checkpoint inhibitor nivolumab combined with the chemotherapy backbone AVD, compared to the brentuximab vedotin-AVD regimen in advanced-stage classic Hodgkin lymphoma. Such findings highlight the potential of harnessing the immune system to enhance frontline cancer control while mitigating treatment-related adverse events. Dr. Alex Herrera, an expert in lymphoma therapeutics, will elucidate these findings and their implications for clinical practice.

Expanding beyond traditional targets, novel BAFF receptor (BAFFR)-CAR T cells, designated PMB-CT01, exhibit promising durable responses and manageable toxicity in patients with relapsed or refractory B-cell lymphomas, including those with prior failure of CD19-directed therapies or CD19-negative disease phenotypes. This advancement underscores the strategic diversification of antigen targets in CAR T cell therapy to circumvent antigen escape and resistance mechanisms intrinsic to B-cell malignancies, an area led by Dr. Elizabeth Budde.

Addressing mantle cell lymphoma, an interim phase II study evaluates the combination of glofitamab, lenalidomide, and venetoclax (GLOVe) in treatment-naïve high-risk patients. Early response and safety metrics post-stage 1 enrollment suggest enhanced therapeutic synergy leveraging an antibody-based bispecific approach alongside targeted agents. Such combination regimens aim to overcome the aggressive biology characterizing mantle cell lymphoma, as presented by Dr. Tycel Phillips.

City of Hope’s expertise extends to multiple myeloma, where research on the safety and efficacy of out-of-specification ciltacabtagene autoleucel (cilta-cel), a BCMA-targeted CAR T cell therapy, addresses challenges inherent in relapsed or refractory disease settings. Dr. Azra Borogovac will present data emphasizing real-world applicability of cellular therapies manufactured under stringent quality parameters, illustrating the balance between regulatory stringency and urgent clinical need.

Transplantation medicine at City of Hope ventures into total marrow and lymphoid irradiation (TMLI) combined with fludarabine-melphalan conditioning for matched donor hematopoietic cell transplantation in older patients with relapsed/refractory hematologic disease. This innovative conditioning regimen offers a refined radiation dose distribution to optimize transplant efficacy and reduce off-target toxicity. Dr. Monzr M. Al Malki’s contributions in refining transplant conditioning protocols address the crucial need to expand transplant candidacy among older and comorbid populations.

Moreover, the institution is pioneering first-in-human trials involving allogeneic CD6-CAR regulatory T cells (tregs) to mitigate chronic graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation. This cellular therapy harnesses immune modulation to restore tolerance and thymic homeostasis, marking a potentially paradigm-shifting approach to one of transplantation’s most formidable complications. Insights into a Toll-like receptor 4 (TLR4) and heat shock protein 70 (HSP70) efferocytic program in thymic macrophages further elucidate mechanisms sustaining thymic output and immune reconstitution, as studied by City of Hope scientists.

Apart from scientific presentations, City of Hope is spearheading educational initiatives critical for disseminating cutting-edge knowledge. The 14th Annual BMT & Cell Therapy Winter Workshop, co-chaired by Dr. Marcel van den Brink, embodies a comprehensive platform addressing emergent themes in cellular therapies and transplantation. Additional symposia explore the latest standards in B-ALL treatment employing off-the-shelf bispecific antibodies and integrate functional with genomic precision medicine in blood cancers, facilitating a multidisciplinary treatment strategy.

A notable scientific workshop led by Dr. Pamela Becker focuses on the integration of functional assays and genomic data, propelling personalized hematologic malignancy therapies from bench to bedside. This synthesis of molecular insights and clinical phenotypes is essential for tailoring interventions that optimize efficacy and curtail resistance. Concurrently, Dr. van den Brink presents novel intersections between the microbiome, diet, and cancer immunotherapy, unveiling how host-environment interactions influence therapeutic outcomes.

In tackling infectious complications post-cellular therapies, educational spotlights led by Dr. Randy Taplitz delineate measures to reduce infection risks in immunocompromised patients. These guidelines are paramount to improving survival and quality of life, given the vulnerability induced by immune ablative treatments and prolonged cytopenias. City of Hope’s multifaceted approach encompasses not only therapeutic innovation but also comprehensive patient care paradigms.

Collectively, City of Hope’s robust presence at ASH 2025 illustrates a commitment to advancing hematology through translational research, precision medicine, and educational leadership. Their integrated model of innovative clinical trials, cutting-edge cellular therapy development, and rigorous biological discovery is setting new benchmarks in blood cancer treatment worldwide. This synthesis of expertise and technology promises to reshape therapeutic landscapes and deliver hope to patients battling some of the most challenging malignancies.

Subject of Research: Hematologic malignancies including leukemia, lymphoma, multiple myeloma, and transplantation therapies.

Article Title: City of Hope Unveils Transformative Advances in Blood Cancer Therapies at ASH 2025

News Publication Date: December 2024

Web References:
https://www.cityofhope.org/about-city-of-hope/leadership-team/marcel-van-den-brink
https://submit.hematology.org/program/session/117545
https://www.cityofhope.org/patients/find-a-doctor/ibrahim-aldoss
https://www.cityofhope.org/patients/find-a-doctor/alex-herrera
https://www.cityofhope.org/patients/find-a-doctor/elizabeth-budde
https://www.cityofhope.org/patients/find-a-doctor/tycel-phillips
https://www.cityofhope.org/patients/find-a-doctor/lindsey-murphy
https://www.cityofhope.org/patients/find-a-doctor/azra-borogovac
https://www.cityofhope.org/patients/find-a-doctor/monzr-al-malki
https://www.cityofhope.org/patients/find-a-doctor/amandeep-salhotra
https://www.cityofhope.org/patients/find-a-doctor/pamela-becker
https://www.cityofhope.org/patients/find-a-doctor/randy-taplitz

Keywords: Hematology, Blood cancer, Leukemia, Lymphoma, Multiple myeloma, Cancer immunology, Cellular therapies, CAR T cell therapy, Hematopoietic cell transplantation, Precision medicine, Immunotherapy, Graft-versus-host disease

At the core of this research lies the elegant biology of stem cells, which possess the remarkable ability to differentiate into various specialized cell types, governed by tightly regulated genetic programs. The team’s challenge was to decode the complex genetic instructions that prompt a stem cell to commit specifically to a blood lineage. To tackle this, Dr. Bigas’ lab performed an unbiased, genome-wide screen in the murine model, systematically testing thousands of genes to identify those responsible for steering embryonic stem cells toward becoming hematopoietic progenitors. Their perseverance paid off when they uncovered a combination of seven critical genes that, when activated in a precise temporal manner, successfully reprogrammed mouse embryonic stem cells into HSPCs.

These newly induced HSPCs were not only phenotypically similar to natural blood stem cells but also demonstrated functional competence in vivo, as they engrafted in adult mice and regenerated a fully operational hematopoietic system. This system included the production of diverse blood cell lineages essential for immune defense, oxygen transport, and clotting. The functional validation of these lab-generated cells marks an essential milestone, proving that targeted gene activation can recapitulate the complexity of blood stem cell development, a feat that opens new therapeutic avenues.

Critically, the implications extend beyond mouse models. Dr. Bigas emphasizes the evolutionary conservation of these genes, noting their high sequence similarity across species, including humans. This conservation underpins the hypothesis that the mechanisms controlling stem cell fate and differentiation are fundamentally shared, suggesting that the mammalian blueprint revealed by this study could be applicable in human systems. Current efforts are underway to translate these findings to human embryonic stem cells, an essential step toward clinical application.

This breakthrough is part of a larger ERC synergy-funded initiative titled "Making Blood," which aspires to establish a cutting-edge platform capable of manufacturing human HSPCs on demand. Should this endeavor succeed, it could herald a new era in the treatment of blood-related disorders, where patients no longer require compatible donors for bone marrow transplantation—a procedure that often involves significant logistical and immunological challenges.

The research, recently published in the esteemed journal Blood, sheds light on the intricate gene regulatory networks that define hematopoietic fate decisions. By employing an unbiased genome-wide approach rather than relying on candidate gene trials, the team ensured a comprehensive and objective discovery process. Such thoroughness enhances the robustness of the findings and offers an expanded genetic toolkit for synthetic biology approaches aimed at blood regeneration.

Importantly, the study integrates developmental biology with translational medicine. Collaborations with experts in pediatric and developmental leukemia, Dr. Clara Bueno and Dr. Pablo Menéndez, have contextualized the importance of these genes in human disease, reinforcing the potential for targeted genetic manipulation to correct hematopoietic deficiencies or malignancies born from aberrant stem cell differentiation.

The potential of producing HSPCs ex vivo with precise genetic programming holds transformative promise for regenerative therapies, immune system reconstitution, and personalized medicine. It challenges current paradigms in transplantation biology, where matching donor and recipient immune profiles remains a critical barrier. By generating stem cells that can be tailored to individual patient needs, this technology could circumvent issues of compatibility and graft-versus-host disease.

The pathway forward, however, is complex. Translating murine genetic programs to human stem cells requires meticulous validation of gene function, timing, and expression levels, as minor deviations may result in incomplete or aberrant differentiation. Additionally, ensuring the safety and stability of genetically reprogrammed cells before clinical use is paramount, requiring comprehensive preclinical studies and regulatory scrutiny.

This work also highlights the synergistic power of interdisciplinary research centers such as the Josep Carreras Leukaemia Research Institute and the Hospital del Mar Research Institute, both recognized for excellence in biomedical science and translational research. Their combined expertise in hematology, oncology, stem cell biology, and clinical research facilitates rapid movement from bench to bedside, accelerating the development of novel therapies.

Funding from national and European scientific bodies, along with prestigious foundations, underscores the strategic importance placed on regenerative medicine for hematological disorders. Investment into projects like “Making Blood” reflects a broader commitment to harnessing the full potential of stem cells to address unmet clinical needs, including leukemia, anemia, and immunodeficiencies.

As research progresses, the scientific community remains vigilant but optimistic. Dr. Bigas’ group continues to unravel the complex genetic landscapes governing stem cell fate, poised to unlock further biological secrets and deliver therapeutic breakthroughs. Their work stands at the nexus of molecular biology, genetics, and clinical innovation, capturing imaginations and catalyzing hope among patients and researchers alike.

This landmark discovery revives the vision of producing a renewable source of healthy blood stem cells, potentially reshaping the management of hematological diseases. It paves the way for future innovations where laboratory-engineered cells could replace damaged or diseased marrow, offering cures where none existed before. The era of regenerative hematology may soon move from conceptual ambition to clinical reality.

Subject of Research: Cells

Article Title: An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells

News Publication Date: 10-Apr-2025

Web References:

• Blood Journal Article
• Josep Carreras Leukaemia Research Institute
• Bigas Lab Stem Cells and Cancer Research

References:
Luis Galan Palma, Gayathri M Kartha, Maria Maqueda, Mercedes Barrero, Eric Canton, Arnau Iglesias, Jessica Gonzalez Miranda, Patricia Herrero Molinero, Raul Torres-Ruíz, Bernhard Payer, Clara Bueno, Pablo Menendez, Lluis Espinosa, Anna Bigas; An unbiased genomewide screen uncovers 7 genes that drive hematopoietic stem cell fate from mouse embryonic stem cells. Blood 2025; blood.2024027742. doi: 10.1182/blood.2024027742

Image Credits: Credit: Hospital del Mar Research Institute

Keywords: Stem cells, Blood cells, Bone marrow cells, Bone marrow

Chronic Myeloid Leukemia (CML) stands as a prominent example of how molecular genetics has revolutionized treatment paradigms. Traditionally diagnosed through the observation of leukocytosis and the presence of immature myeloid cells in peripheral blood, CML is primarily linked to the BCR::ABL1 fusion gene. This genetic anomaly arises from a translocation involving the Philadelphia chromosome, which catalyzes the overactivity of tyrosine kinase, promoting unchecked cellular proliferation. The introduction of imatinib—a small molecule tyrosine kinase inhibitor—has profoundly altered the prognosis for CML patients, with many experiencing rapid normalization of white blood cell counts. However, as resistance mutations have emerged, the importance of ongoing molecular monitoring has become paramount. Techniques such as quantitative PCR, fluorescence in situ hybridization (FISH), and karyotyping are now routine elements of care, enabling clinicians to adapt treatment in response to changing genetic landscapes.

Beyond CML, the realm of BCR::ABL1-negative myeloid neoplasms offers additional insights into the versatility of molecular genetic testing. Conditions such as chronic neutrophilic leukemia (CNL) and chronic eosinophilic leukemia (CEL) do not harbor the BCR::ABL1 fusion yet still present characteristic genetic profiles that inform their diagnosis and management. For example, CNL is frequently associated with CSF3R mutations, while classical myeloproliferative neoplasms like polycythemia vera and essential thrombocythemia often feature mutations in the JAK2, MPL, or CALR genes. The application of next-generation sequencing facilitates the simultaneous profiling of these multiple genetic markers, thus optimizing the diagnostic process and aiding prognostication.

In the evolving landscape of hematological malignancies, a newly recognized subgroup of myeloid and lymphoid neoplasms characterized by eosinophilia and tyrosine kinase fusion genes provides a fertile ground for molecular interventions. Such genetic anomalies, including PDGFRA, PDGFRB, and FGFR1 fusions, underscore the need for rapid molecular diagnostics. Detecting imatinib-sensitive fusions can lead to significantly improved patient outcomes, making targeted sequencing and FISH essential tools in clinical settings. The accelerated pace of molecular research will likely lead to even more refined diagnostic techniques and therapeutic options in the forthcoming years.

Myelodysplastic syndromes (MDS), defined by cytopenia and abnormal morphology, represent another area where genetic insights promise improved clinical outcomes. Various genetic alterations, such as deletions on chromosomes 5, 7, and 20, and mutations in splicing factor genes (e.g., SF3B1, SRSF2), are critical to understanding the disease’s progression and guiding treatment choices. In cases where MDS evolves into acute myeloid leukemia (AML), understanding the mutational landscape—including the presence of adverse mutations like those in TP53 and FLT3—becomes vital. High-throughput sequencing technologies allow for the comprehensive analysis necessary to address the complexity inherent in these disorders.

Acute myeloid leukemia elucidates the utility of genetic testing in refining therapeutic strategies. Approximately 50% of AML cases demonstrate specific chromosomal abnormalities with implications for prognosis. While certain mutations, such as PML::RARA, are associated with favorable outcomes, others, including those affecting FLT3 and KMT2A, are linked to poor prognosis. Molecular profiling not only aids in classifying these heterogeneous diseases but also in tailoring interventions such as targeted therapies that significantly enhance survival rates.

In lymphoproliferative disorders like Chronic Lymphocytic Leukemia (CLL) and small lymphocytic lymphoma (SLL), genetic factors similarly dictate treatment pathways. The mutational status of IGHV genes has emerged as a critical prognostic indicator, with hypermutated IGHV correlating with better patient outcomes. Additionally, the identification of cytogenetic abnormalities involving deletions of 13q, 11q, and 17p, coupled with mutations in TP53 and NOTCH1, profoundly influence treatment decisions and survival prospects. With the advent of Bruton tyrosine kinase inhibitors like ibrutinib, the management of CLL/SLL has been transformed; however, continuous surveillance for resistance mutations is necessary to maintain the efficacy of these therapies.

The rich genetic underpinnings of low- and high-grade B-cell lymphomas elucidate the complexity of hematological cancers. Low-grade lymphomas such as follicular lymphoma often exhibit BCL2, BCL6, or CCND1 gene translocations. Conversely, high-grade B-cell lymphomas, particularly Burkitt lymphoma, present with MYC rearrangements that are critical for diagnosis. The identification of concurrent MYC and BCL2/BCL6 rearrangements marks the emergence of “double-hit” lymphomas, necessitating aggressive treatment approaches that reflect the urgency and complexity of these conditions.

T-cell lymphomas also illustrate the significant role of genetic profiling in guiding clinical decisions. Anaplastic large cell lymphoma is characterized by ALK gene rearrangements, highlighting the importance of targeted therapies. Moreover, mutations in RHOA, IDH2, and STAT3/5B contribute to the diverse classification of peripheral T-cell lymphoma and large granular lymphocytic leukemia. Accurate detection of clonal T-cell receptor (TCR) gene rearrangement remains a cornerstone of distinguishing between reactive and neoplastic processes within these disorders.

In conclusion, molecular genetic testing represents a seismic shift in the diagnosis and management of hematopoietic and lymphocytic neoplasms. The integration of high-throughput genomic technologies and advanced bioinformatics tools fosters richer disease classifications and enhances personalized treatment paradigms. This ongoing scientific endeavor aims to refine molecular assays and facilitate the discovery of novel therapeutic options, thereby aspiring to improve patient outcomes across a spectrum of complex hematological malignancies.

As investigations into these malignancies continue to unfold, the hope remains that the wealth of genetic information will translate into more effective interventions, ultimately paving the way for a new era in cancer treatment rooted in science and technology.

Subject of Research: Applications of Molecular Genetic Testing in Hematopoietic and Lymphocytic Neoplasms
Article Title: Applications of Molecular Genetic Testing in Hematopoietic and Lymphocytic Neoplasms
News Publication Date: 25-Dec-2024
Web References: https://www.xiahepublishing.com/journal/jctp
References: DOI: 10.14218/JCTP.2024.00042
Image Credits: Credit: Weiqiang Zhao

Keywords: Cancer treatments, Gene targeting, Molecular targets, Regulatory genes, Myeloid leukemia, Tumor morphology, Clinical research